Adavivint-SM04690-DataSheet-生命科學(xué)試劑-MedChemExpress

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemEAdavivintCat.No.:HY-109049CASNo.:1467093-03-3Synonyms:SM04690;Lorecivivint分?式:C??H??FN?O分?量:505.55作?靶點:Wnt作?通路:StemCell/Wnt儲存?式:Powder-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性數(shù)據(jù)體外實驗DMSO:25mg/mL(49.45mM;Needultrasonicandwarming)H2O:<0.1mg/mL(insoluble)MassSolvent1mg5mg10mgConcentration制備儲備液1mM1.9780mL9.8902mL19.7804mL5mM0.3956mL1.9780mL3.9561mL10mM0.1978mL0.9890mL1.9780mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；?旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。儲備液的保存?式和期限：-80°C,6months;-20°C,1month。-80°C儲存時，請在6個?內(nèi)使?，-20°C儲存時，請在1個?內(nèi)使?。體內(nèi)實驗請根據(jù)您的實驗動物和給藥?式選擇適當?shù)娜芙?案。以下溶解?案都請先按照InVitro?式配制澄的儲備液，再依次添加助溶劑：(為保證實驗結(jié)果的可靠性，澄的儲備液可以根據(jù)儲存條件，適當保存；體內(nèi)實驗的?作液，建議您現(xiàn)?現(xiàn)配，當天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的?式助溶)1/2MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemE1.請依序添加每種溶劑：10%DMSO>>40%PEG300>>5%Tween-80>>45%salineSolubility:≥2.5mg/mL(4.95mM);Clearsolution2.請依序添加每種溶劑：10%DMSO>>90%(20%SBE-β-CDinsaline)Solubility:≥2.5mg/mL(4.95mM);Clearsolution3.請依序添加每種溶劑：10%DMSO>>90%cornoilSolubility:≥2.5mg/mL(4.95mM);ClearsolutionBIOLOGICALACTIVITY?物活性Adavivint(SM04690;Lorecivivint)?種有效的，選擇性的典型的Wnt信號通路抑制劑，在SW480細胞中，??通量TCF/LEF報告因?qū)嶒?，測得EC50值為19.5nM。IC50&TargetEC50:19.5nM(Wnt,SW480cell)[1]體外研究Adavivint(SM04690)isapotentandselectiveinhibitorofWntsignaling,withanEC50of19.5nMviaahigh-throughputTCF/LEF-reporterassayinSW480coloncancercells,andshowsnoeffectonSV40luciferasereporter.Adavivintenhancesaggregationofhumanmesenchymalstemcells(hMSCs)withanEC50of10nM.Adavivint(30nM)protectschondrocytesfromcatabolicbreakdowninvitro[1].體內(nèi)研究Adavivint(0.3μg)enhancescartilagerepairandprotectionintheratacutecruciateligamenttearandpartialmedialmeniscectomyosteoarthritis(ACLT+pMMxOA)model[1].戶使?本產(chǎn)品發(fā)表的科研?獻?CellOncol.2022Oct21.?MolCarcinog.2022Oct12.?Bone.2022Feb23;116372.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].DeshmukhV,etal.Asmall-moleculeinhibitoroftheWntpathway(SM04690)asapotentialdiseasemodifyingagentforthetreatmentofosteoarthritisoftheknee.OsteoarthritisCartilage.2018Jan;26(1):18-27.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplications.Forresear